Paper Details

  1. Home
  2. Paper Details

Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias.

Author: FujiiHironori, HiroseChiemi, HishidaShiori, IiharaHirotoshi, KiyamaShigeru, KobayashiRyo, MakiyamaAkitaka, MatsuhashiNobuhisa, MatsuokaSerika, OhataKoichi, SuzukiAkio, TajimaJesse Yu, TakahashiTakao, WatanabeDaichi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Trifluridine-tipiracil (TAS-102) is a medication used to treat colorectal cancer. Some studies have shown that patients who develop severe neutropenia, a low white blood cell count, while taking TAS-102 have a better survival rate. However, more research is needed to determine if this is truly the case. Additionally, the association between severe neutropenia and survival in patients taking TAS-102 with bevacizumab remains unclear.
Paper Details　
Original Abstract of the Article :
Several studies have reported an association between severe neutropenia and long-term survival in patients treated with trifluridine-tipiracil (TAS-102). Because some of these studies failed to address immortality time bias, however, their findings should be interpreted with caution. Additionally, t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10634158/

データ提供：米国国立医学図書館（NLM）

Severe Neutropenia: A Storm in the Desert of Cancer Treatment

The field of [oncology] is constantly seeking to improve the effectiveness and safety of [cancer treatments]. This study investigates the prognostic impact of [severe neutropenia], a serious side effect of [chemotherapy], in patients with [colorectal cancer] who are treated with [TAS-102 and bevacizumab]. The researchers conducted a study to assess the relationship between [severe neutropenia] and [long-term survival] in this patient population. The study aimed to clarify the potential association between [severe neutropenia] and [survival] while addressing [immortal-time bias], a common issue in survival analysis.

Severe Neutropenia: A Complex Factor in Cancer Survival

The study revealed that [severe neutropenia] is a complex factor in the treatment of [colorectal cancer] with [TAS-102 and bevacizumab]. While some studies have suggested a link between [severe neutropenia] and [long-term survival], the study emphasizes the need to account for [immortal-time bias] to ensure accurate conclusions. The study highlights the importance of careful monitoring and management of [neutropenia] in patients receiving [TAS-102 and bevacizumab] to ensure optimal treatment outcomes.

Navigating the Desert of Cancer Treatment: A Focus on Neutropenia

This study provides valuable insights into the impact of [severe neutropenia] in patients with [colorectal cancer] undergoing treatment with [TAS-102 and bevacizumab]. The research highlights the need for continued research to understand the complex interplay between [neutropenia], [chemotherapy], and [survival]. The study also emphasizes the importance of patient monitoring and the development of effective strategies to manage [neutropenia]. As a researcher, I am always drawn to the challenges and complexities of cancer treatment, and I am inspired by the dedication of healthcare professionals who work tirelessly to improve patient outcomes.

Dr.Camel's Conclusion

The study emphasizes the need to address immortal-time bias when investigating the prognostic impact of severe neutropenia in patients with colorectal cancer treated with TAS-102 and bevacizumab. Further research is needed to clarify the association between severe neutropenia and survival in this patient population.

Date :
  1. Date Completed 2023-11-10
  2. Date Revised 2023-11-11
Further Info :

Pubmed ID

37940878

DOI: Digital Object Identifier

PMC10634158

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.